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Abstract. Even though the accrual of transcripts is implicated 
in distinct disease states, our knowledge regarding their func-
tional role remains obscure. The CRISPR system has surged at 
the forefront of genome engineering tools in the field of RNA 
modulation. In the present review, we discuss some exciting 
applications of the CRISPR system, including the manipulation 
of RNA sequences, the visualization of chromosomal loci in 
living cells and the modulation of transcription. The CRISPR 
system has been documented to be very reliable and specific 
in altering gene expression, via leveraging inactive catalyti-
cally dead CRISPR-associated protein 9 (Cas9). In the present 
review, the CRISPR system is presented as an eminent tool for 
the meticulous analysis of gene regulation, loci mapping and 
complex pathways.
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1. Mechanisms of action of the CRISPR system
In general, the main function of the CRISPR system is 
mediated by the CRISPR-associated protein (Cas) nuclease, 
which interacts with DNA and generates double-strand breaks 
in DNA sequence, matching the broken genomic region with 
a single guide RNA (sgRNA). The sgRNA is a chimeric 
RNA which consists of programmable CRISPR RNA and a 
trans-activating RNA (tracrRNA) (1). More specifically, the 
CRISPR-Cas system includes a cluster of proteins, categorized 
into Class 1 (Types I, III and IV) and Class 2 (Types II, V 
and VI) (2), all of which constitute specific RNA-guided DNA 
endonuclease (Cas) proteins (1-4). A distinct characteristic 
of Cas proteins is that they are driven by RNAs, and not by 
other proteins, in recognizing the desired DNA sequence. 
The CRISPR-Cas subtype that is usually selected is Class 2, 
which generally exploits Cas9 nuclease (1,3,4). As regards 
the RNA-mediated action of the CRISPR system, it has been 
reported that the 100 bp sgRNA forms complementary bonds 
with the target DNA sequence of 17-20 nucleotides, via Watson-
Crick base-pairing and the tracrRNA is the component which 
Cas9 nuclease binds to. Specifically, the sgRNA recognizes the 
target sequence located upstream of a triplicate sequence named 
the protospacer adjacent motif (PAM), given that the PAM 
motif recruits Cas9 nuclease at the site of DNA cleavage (5) 
(Fig. 1). Of note, the PAM sequence plays a determinant role 
in recognizing the correct DNA sequence and preventing the 
direction of RNA to self-targets and non-specific sequences (6). 
In the case of Cas9 that is derived from Streptococcus pyogenes, 
the motif of the PAM sequence may be composed of any base, 
followed by two additional guanine bases (7). In addition, 
the superiority of Cas9 nuclease has been demonstrated not 
only against other nucleases, but also against the silencing 
mechanism, known as RNA interference (RNAi), that has been 
used extensively for the disruption of gene expression. Another 
important aspect is that the CRISPR genome editing tool acts 
in the nucleus, whereas the RNAi system exerts its action in 
the cytoplasm. RNAi seems to have prevalent unpredictable 
off-target effects (8) due to the extensive modulation of 
microRNAs (miRNAs or miRs) (9) or partial silencing (10). 
Compared to RNAi techniques, the CRISPR system functions 
at the DNA level, resulting in the permanent inactivation 
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of a given gene, with fewer off-target effects. On the other 
hand, the main disadvantage of the CRISPR system is its low 
efficiency in some cases, as its effects are undetectable in a cell 
population, thus prompting researchers to optimize the system 
for implementation in the clinical setting.
As regards the challenges associated with the CRISPR 
technique, the method has been referred to sustain its activity 
even if the sgRNA and the target sequence do not form 
complementary bonds in 3 sequential bases at the 3' terminal 
end of sgRNA (11). It has also been mentioned that the scale of 
side-effects begins at 10 and exacerbates to 1,000. However, the 
phenomenon can be partially rescued with the careful design 
of guide RNA (gRNA) (12); characteristically, the specificity 
of the CRISPR system can be accelerated by reducing the 
sequence of gRNA to 17-18 nucleotides (13).
2. Controlling gene expression through the CRISPR system
Advances in the CRISPR engineering tool have led to the creation 
of inactivated (catalytically dead) Cas9 (dCas9). Modified Cas9 
involves the following: Catalytic substitution (D10A) in the 
RuvC domain, the abolishment of endonuclease activity and 
catalytic replacement (H847A) in the HNH domain.
dCas9 bound to DNA elements alone may inhibit the 
transcription either at the initiation or the elongation level. 
Specifically, it has been demonstrated that dCas9 can impair 
transcription, excluding the potential of crosstalk between 
cis-acting motifs of any promoter with trans-acting transcrip-
tion factors during transcriptional initiation (14). In the process 
of transcriptional elongation, the DNA is not cleaved due to the 
lack of dCas9 endonuclease activity and the RNA polymerase 
is sterically prevented, causing transcriptional stalling in a 
strand-specific manner (14). It is evident that the association 
between the sgRNA-dCas9 complex and RNAP is responsible 
for transcriptional elongation.
Apart from simply blocking the transcription of target genes, 
it may be possible to couple the dCas9 protein with numerous 
regulatory domains, modulate different biological processes 
and generate functional outcomes. Importantly, the inactivated 
domain of Cas9 can be combined with activator or repressor 
domains, thus controlling gene expression. The inactivated 
domain of Cas9 can be fused to epigenetic modifiers, thus 
paving the way in the control of gene expression and epigenetic 
modifications in a fast and reliable manner (15) (Fig. 1).
In the case of dCas9, the DNA is not cleaved due to the lack 
of Cas9 endonuclease activity. The dCas9 can be fused to tran-
scription factor domains or epigenetic modifiers or fluorescent 
molecules, thus determining the control of gene expression or 
imaging, respectively.
Overall, the control of gene expression can be mediated 
in a spatial-temporal manner, via the binding of dCas9 with a 
repressor domain, such as Kruppel-associated box (KRAB) (16) 
or an activator domain, such as VP16 and VP64 (17), thereby 
inhibiting or triggering gene expression, respectively. On the 
one hand, the interruption of transcription in target genes can 
be culminated, via a combination of dCas9 with transcriptional 
repressor domains (KRAB or SID) and epigenetic modifiers 
that are responsible for epigenetic silencing (17,18). In CRISPR 
interference (CRISPRi), the transcriptional silencing is very 
high at both the prokaryotic and the eukaryotic level (14). Of 
note, CRISPRi can repress the transcription of an endogenous 
gene or of multiple genes independently in bacterial and 
mammalian cells, as illustrated by Mandegar et al by eliminating 
the factors, octamer-binding transcription factor 4 (OCT4), 
Figure 1. The CRISPR platform for gene editing, genomic regulation and imaging.
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NANOG and sex determining region Y)-box 2 (SOX2), 
the kinases, Rho-associated, coiled-coil-containing protein 
kinase 1 (ROCK1) and glycogen synthase kinase 3 (GSK3)-β, 
a cardiac mesoderm transcription factor, and cardiac disease-
associated genes [BCL2-associated athanogene 3 (BAG3), 
myosin binding protein C (MYBPC)3 and human ether-
a-go-go-related gene (hERG)] in induced pluripotent stem 
cells (iPSCs) (19). The repressor activity of CRISPRi has only 
been validated using quantitative fluorescence assays and 
native elongating transcript sequencing (20). On the other hand, 
Cas9 nuclease can boost gene transcription via coupling with 
VP16/VP64 or p65 activation domains. It is noteworthy that the 
level of transcriptional upregulation depends on the presence of 
single (18,21-23) or multiple sgRNAs which have a cumulative 
effect on transcription (21-23). In order to augment the activation 
signal, researchers have used a SunTag array, in which dCas9 
is fused to a protein platform loaded with 24 epitopes, each of 
which is recognized by a single chain variable fragment (scFv) 
of antibody, which is in turn linked to activator effector 
domains like VP64 (24). For example, it has been reported that 
CXCR4 expression is more prominently augmented (50 fold) 
with the SunTag array, as compared to a 2-fold increase that 
is mediated by the action of dCas9-VP64 (25). In the same 
context, the significant upregulation of gene expression can be 
mediated by ‘in trans’ interactions through synergistic activa-
tion mediator (SAM). The SAM approach is reportedly based 
on bringing activators (e.g., p65-HSF1) fused with MS2 bacte-
riophage coat protein and Cas9 loaded with VP64 to interact 
with sgRNAs containing MS2 target sites (26). Furthermore, a 
method of enhancing the activation of gene expression though 
dCas9-VPR (VP64, p65 and Rat) has been presented, which 
specifically exploits the synergistic power of distinct activating 
factors ‘in cis’ (27).
Based on the ability of RNA to function as a scaffold, 
Zalatan et al (28) were inspired to design a CRISPR sgRNA 
sequence which was fused to single RNA hairpin domains via a 
linker of 2 bases, using viral sequences that recruit the assembly 
of RNA-binding factors. In turn, the RNA-binding factors 
orchestrated the landscape for transcriptional activation or 
suppression of target genes, via interaction with the appropriate 
transcription factors. As a result, the expression of multiple 
genes was controlled simultaneously, either by activation or 
suppression, whereas at the same time this unique system 
allowed for large scale screening of pairwise combinations 
of genes, many of which constituted important regulators of 
tumorigenesis (28).
In all cases, there are certain factors that influence the 
outcome of upregulated or attenuated gene expression. The 
orientation of sgRNAs relative to the transcriptional start 
site (TSS) of genes and the selection between amino terminal 
or carboxyterminal fusion of dCas9 with effector domains 
may be of fundamental importance in determining the end 
transcriptional result. For example, it has been noted that the 
well-established VPR system of transcriptional activation can 
also be exploited for the suppression of endogenous genes when 
gRNAs are orientated downstream of the TSS (29).
Despite the considerable number of studies on 
tumorigenesis, there is a certain paucity of data pertinent to 
various regulatory elements, including enhancers. For example, 
the functional involvement of enhancers in tumorigenesis 
has been validated through their capacity to orchestrate gene 
expression profiles (30). Classical research methods, such 
as high-throughput reporter assays, have been employed to 
address enhancer properties (31); however, inadequate results 
have been produced. Nowadays, the revolutionary CRISPR 
approach provides us with the opportunity to monitor the 
distribution of regulatory elements and determine their 
functional properties. Impressively, Xie et al (32) devised a 
conceptual framework (Mosaic-seq), which utilizes a CRISPR 
barcoding approach in combination with single-cell RNA 
sequencing by Drop-seq, to quantitatively evaluate enhancer 
function and identify the elements of super enhancers (32). 
Specifically, K562 cells infected with dCas9 fused to the 
KRAB domain, resulting in the repression of gene expression 
at potential enhancers; subsequently, the cells were infected 
with a labeled sgRNA library against possible enhancers 
and assorted following the application of antibiotic tests for 
RNA sequencing (Drop-seq). Mosaic-seq has offered insight 
into enhancer penetrance, endogenous activity and a deeper 
understanding of the hierarchy of the constituents that comprise 
super enhancers in a genome-wide, single-cell and unbiased 
manner (32).
For the study of promoter sequences, Chiba et al used the 
CRISPR system to trigger cancer-related TERT promoter dele-
tions, in order to delineate the consequences in neoplastic as 
well as normal cells, such as human embryonic stem cells (33). 
In other words, the particular genome engineering tool allows 
researchers to identify the cause of aberrantly long telomeres 
in tumorigenesis.
3. Approaches for spatiotemporal control of gene expression
The CRISPR system can be further evaluated to function in 
a spatial-temporal manner and many scientific advances have 
been made in this direction. One method that has garnered 
significant attraction is gene manipulation according to 
induction by light. For example, the heterodimerization of CRY2 
and CIB1 proteins has been observed in response to 450 nm 
light, allowing the assembly of VP64 to dCas9 (34). Another 
method supports that Cas9 nuclease is uncoupled to its gRNA 
in the absence of light. The researchers have substantiated that 
a lysine residue (K866) is responsible for the activation of Cas9 
nuclease, given that conformational changes are performed 
upon binding of sgRNA and UV illumination (35). Another 
method has employed the segregation of Cas9 nuclease and 
its conjunction with photoinducible partners. The action of 
the CRISPR system is performed only after irradiation with 
blue light in which the distinct segments of Cas9 nuclease are 
assembled in a complex (36). Last but not least, the inducible 
effect of the CRISPR system on gene expression can be 
mediated by a chemical stimulus (doxycycline, rapamycin and 
4-hydroxytamoxifen) (37,38).
4. Progress made in elucidating the role of non-coding 
RNAs using the CRISPR system
Despite the reported advances in generating schemes for the 
insertion or elimination of genes, there appears to be a lack of 
strategies that can be applied at the RNA level. The CRISPR 
approach is not restricted to the modification of the coding 
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compartment of the cell, but it also applies to the non-coding 
compartment, which usually has a significant regulatory 
functions.
The advantage of CRISPRi over RNAi is that the former 
is an exogenous system that does not intervene with endog-
enous processes and facilitates the study of long-noncoding 
RNAs (lncRNAs), as well as miRNAs. The CRISPRi system is 
based on the action of catalytically dCas9 which does not exert 
endonuclease activity (14,17). Importantly, dCas9 abrogates the 
transcriptional machinery, thus hindering gene expression by 
exploiting the sgRNA sequence only, and maps the presence 
of cis regulatory element binding in the lactose regulatory 
network (19). For the CRISPRi system to function properly, 
sgRNAs should be designed such that the distance between the 
TSS and the target should be approximately 300 bp (39), so as 
to avoid mismatches and side-effects.
In modulating gene expression, lncRNAs have been shown 
to play a fundamental role in both normal developmental 
processes and in abnormal cellular states such as cancer, thus 
highlighting the need for further investigation (40). lncRNAs 
have been reported to be modified by the CRISPR approach 
only (41). The CRISPR system acts by either disrupting the 
target lncRNA or by inserting RNA-destabilizing elements 
or by introducing a poly-adenylation stop signal, thus leading 
to gene replacement or promoter disruption (40). Several 
research groups have employed CRISPR strategies to disrupt 
the function of lncRNAs in mouse models. The ablation of the 
Malat1 lncRNA constitutes an indicative example of the above 
strategy (42). An alternative strategy supports the replacement 
of an lncRNA sequence with a marker sequence (such as LacZ), 
thus allowing the monitoring of the reporter gene expression 
as driven by the promoter of the lncRNA (43). However, that 
method was relatively costly and tested on mice that were 
specifically deficient for 18 lncRNAs (43). Notably, it was 
previously demonstrated that the HOXA gene cluster can be 
regulated by the lncRNA transcript known as Haunt. Using the 
CRISPR system, it was found that Haunt lncRNA functioned 
as a roadblock, impairing HOXA gene expression when it was 
assigned as aberrant (44). Therefore, the CRISPR genome engi-
neering tool appears to be the first method for the identifaction 
of the molecular mechanisms mediated by lncRNAs in various 
biological processes.
Nonetheless, the implementation of the CRISPR method 
requires specific information regarding the traits of lncRNAs, 
such as their effect on the ‘cis’ or ‘trans’ expression of genes 
or on the expression of multiple genes. For example, only 
approximately 40% of assigned lncRNAs can be subjected to 
the CRISPR screen, where gene sequences near the lncRNAs 
may be influenced by the action of Cas9 nuclease and the 
danger of no specificity has not been circumvented.
As regards the study of miRNAs, Xiao et al were the first 
group that used the CRISPR method to eliminate large genomic 
regions of 1 Mb in size in zebrafish, thereby suppressing the 
action of miRNAs that constitute 1 or 3% of the zebrafish 
genome (dre-mir-126a or miRNA cluster Chr. 9) (45). In 
particular, the CRISPR method was used to suppress the 
following: miR-137 in ovarian cancer (46), the UCA1 lncRNA 
in bladder cancer (47), as well as the Hotair (HOX transcript 
antisense RNA) (48) and BC200 lncRNAs in breast cancer (49). 
Furthermore, the inverse association between miR-24-3p and 
E3 ubiquitin ligase and the TRIM11 oncogene was previously 
investigated by the CRISPR method, through which the attenu-
ation of colorectal tumor progression was facilitated and a novel 
therapeutic target in colorectal cancer was highlighted (50).
Last but not least, the Molecular Chipper approach was 
previously used to investigate the functional regulatory elements 
involved in the biogenesis of lncRNAs, highlighting important 
cis-domains for miR-142 biogenesis (51). In the same direction, 
Shechner et al demonstrated an innovative CRISPR-Display 
method in studying the functional significance of regulatory 
molecules such as lncRNAs, miRNAs, circular RNAs, 
piwi-interacting RNAs and many others types of RNA (52). 
The pioneering CRISPR-Display platform was designed to shed 
further light on the molecular mechanisms exerted by lncRNAs 
on a spectrum of biological processes, such as epigenetic 
modifications, transcriptional regulation and chromatin 
remodeling. The CRISP-Display platform has allowed 
researchers to evaluate the functionality of RNA molecules, 
either based on their transcriptional profile or on topological 
changes and alterations in the tridimensional landscape (52). A 
characteristic example of exploiting accessory RNA domains 
was demonstrated by Shechner et al, who conjugated the RepA 
domain of Xist with gRNA. Therefore, the repressive action 
of Xist, caused by its association with the RepA domain, was 
unveiled. The CRISPR-Display platform also functions in a 
flexible and multiplex manner, as it facilitates fusing the gRNA 
to a lncRNA and monitoring of the transcription of a reported 
gene with concomitant imaging of another DNA locus, thus 
allowing for simultaneous analysis of several targets based on 
the available RNA motifs (53).
The main characteristic of the CRISP-Display platform is 
the delivery of dCas9 to predetermined DNA loci according to 
the specificity of gRNA and the dCas9 fusion with any of tran-
scriptional effector domains, including VP4 (52). As regards 
the RNA cargos used by Cas9, it was indicated that effector 
domains can be linked to dCas9 nuclease either directly 
(known as ‘direct activation) or indirectly, using aptamers 
which can function as ‘accessory RNA domains’ of 4.8 kb 
in size, with the potential of binding the suitable transcrip-
tional domain (knownas ‘bridged’ activation) without sterical 
barriers, given that the RNA domains can be positioned at the 
5' or the 3' end of gRNA. The only restraint in implementing 
the CRISP-Display approach in all the non-coding RNAs was 
the restricted panel of RNA domains that can be appended to 
sgRNAs (52).
5. Exploiting the CRISPR/Cas approach in the field of 
epigenetics
The etiology of several diseases may be linked to epigenetic 
alterations, which may have a significant impact on the 
transcriptional level or on DNA methylation patterns or 
histone modifications, thus altering diverse biological 
functions such as transcription. It has been demonstrated 
that mutations in inactive nucleases cause them to be fused 
with epigenetic modifiers and the transcriptional landscape 
is reorganized. Stable transcriptional suppression has been 
achieved through fusion of dCas9 with a repression domain 
such as KRAB and DNA methylatransferase (53). Specifically, 
Cas9 nuclease has been successfully fused with the Dnmt3 
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DNA methyltransferases (54) and with the G9a or SUV39H1 
methyltransferase to mediate epigenetic silencing. Notably, 
the synergistic effect of the dCas9 repressor domain fused to 
DNA methyltransferasesDNMT3A and DNMT3L appears 
to be more effective than using the dCas9-repressor domain 
alone (55).
By contrast, the fusion of dCas9 to other epigenetic modula-
tors, such as TET1 demethylase (56), LSD1 histone demethylase 
or the p300 histone acetyltransferase (57) seems to upregulate 
endogenous genes. Nonetheless, experimental methods need 
to be further investigated in order to elucidate the crosstalk 
between epigenetic modifiers and endogenous proteins, as they 
often cause false phenotypes (58).
6. Implementation of the CRISPR system in the field of 
imaging
The organization of chromatin in the nucleus is usually 
addressed as a critical issue. Identifying the principles behind 
chromatin orientation can help in the understanding of how the 
spatial organization of chromatin can affect gene expression. 
For this purpose, FISH technologies that utilize the denaturation 
of double-strand DNA, heating/formamide and the attachment 
of fluorescent probes to denatured DNA have been extensively 
used. The main drawbacks of the available techniques are 
disruption of the genomic structure, restricted resolution and the 
prohibitive expense of oligo probes (59).
Previous data have demonstrated an impressive technique 
to monitor not only the repetitive elements in telomeres, but 
also gene sequences in live cells, circumventing the classical 
problems of fixation and DNA denaturation that emerge 
during FISH technologies or artificial insertions of LacO 
or TetO cassettes (60). Specifically, Chen et al modified a 
form of nuclease Cas9 [coupled with a fluorescent molecule, 
such as enhanced green fluorescent protein (EGFP)] and 
optimized small guide RNA, thus managing to monitor the 
route of desired genomic sequences in live cells and track 
the dynamic nature of chromatin (61). In the meantime, Cas9 
nuclease appeared to be a more powerful as compared to the 
transcription activator-like effector nuclease that had been 
usually used for detecting telomere and satellite DNA (62), 
as Cas9 nuclease has the capacity to label multiple genomic 
sequences in live cells. Consequently, imaging using Cas9 
nuclease proved to be a significant advancement, not only in 
terms of relating chromatin state with gene function, but also 
in understanding the aneuploidy that is usually seen in cancer 
cells (63). In addition, CRISPR imaging appears to be very 
effective in studying interactions among genomic elements 
as compared to other techniques (chromatin conformation 
capture-3C and derivatives such as Hi-C) (64). Importantly, 
Cas9 nuclease was recently modulated to monitor RNA in 
live cells instead of RNA FISH/MeCP2, thus facilitating 
visualization of the endogenous RNA distribution in live 
cells without exogenous tags, and even their accumulation 
in stress granules of live cells (65). A particularly innovative 
technology was devised for the detection of genes within 
undisturbed nuclei of fixed cells and tissues; Cas9 and CRISPR 
repeats (clustered regularly interspaced short palindromic 
repeats) were combined with an RNA sequence to serve as 
probes in identifying the genes of interest at the genome level. 
That approach not only preserved the spatial relationships 
of the genetic elements, which appear very important in 
understanding gene expression, but the process was overall 
remarkably quick (15 min), convenient and amenable to 
diagnostic tests. Previous approaches have used fluorescent 
DNA probes to hybridize to genes of interest, which often 
require heat treatment and disruptive chemicals that distort 
the natural organization of the nucleus.
Furthermore, the combination of inactivated Ca9 and EGFP 
has proven to be very sufficient in monitoring the localization 
of any genomic sequence, apart from the telomeres in which it 
was first applied (61). In this direction, another advantageous 
method for enriching the signal in live cell imaging is to use 
the dCas9-SunTag system, in which fluorescent molecules are 
fused to individual scFv which are located on a protein epitope 
tail fused to dCas9 (24). In addition, phototoxicity has been 
minimized by reducing excitation laser power and subsequently 
by amplifying the signal at a specific target (24). If one 
Figure 2. (A) RNA editing at non-coding RNAs, such as lncRNAs, miRNAs. (B) Modulation of gene expression in a spatial-temporal manner and epigenetic 
regulation using dCas9 coupled to epigenetic modifiers. (C) Genomic imaging using dCas9 fused to a fluorescent marker. lncRNAs, long-noncoding RNAs; 
miRNAs, micro-RNAs; dCas9, inactivated Cas9.
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considers the scaffold properties of sgRNA (50), random RNA 
aptamers could be exploited for the assembly of fluorescent 
molecules (66), instead of using epitopes.
7. Utilizing the CRISPR system in monitoring cell fate
Despite being essential tools in the identification of tumori-
genic genes, pooled genetic screens cannot be used to analyze 
neoplasm cellular complexity and clonality, as the results 
derived from screens can lead to false-negative and -positive 
conclusions (67).
Based on the notion that cancer is a stochastic procedure 
in which cancer cells adapt to the environment by acquiring 
‘de novo’ mutations, researchers have revealed a new barcoding 
system that enables monitoring the fate of cancer subpopula-
tions. Notably, the tumor immune escape is attributed to 
complex tumor heterogeneity, possibly pertaining to the origin 
of cancer cells. In the CRSIPR-barcoding system, a homology 
directed repair mechanism has been used to specifically intro-
duce mutations in cancer cells, along with silent mutations as 
a reference, thus recapitulating the clonal history of cells. It 
has been demonstrated that CRISPR-barcoding is multiplex, 
allowing the remodeling of many mutations in cancer cell popu-
lations and leading to a more comprehensive understanding 
of cellular networks. The effects of distinct drug combina-
tions (gefitinib-WZ4002, ALK inhibitor TAE684-WZ4002, 
gefitinib-trametinib) in prostate cancer cells (PC9 cells) 
harboring either KRAS G12D mutation or EGFR T790M 
mutation or EML4-ALK rearrangement have been deciphered. 
In addition, the effects caused by inactivation of the p53 gene 
(TP53 R273H) in breast cancer cells (MCF7 cells) and colon 
cancer cells (HCT-116 cells) have been identified, whereas 
the expression of adenomatous polyposis coli gene (APC) 
in colon cancer cells (DLD-1 cells) has been abrogated. 
Furthermore, CRISPR-barcoding has been employed to repair 
the ALK-F1174L activating mutation in Kelly neuroblastoma 
cells, resulting in correction of the mutation or in generating 
truncated protein (ALK-STOP barcode). Overall, this new 
CRISPR-barcoding tool has facilitated the monitoring and 
study of cell fate, both in response to therapy and in the absence 
of therapy. The new strategy may be used for the identification 
of any type of genetic modification, is compatible with many 
cancer types and functional assays, but above all it does not 
cause side effects owing to silent mutations, thus paving the 
way for the development of new therapeutic protocols (68).
8. Conclusions
The CRISPR system has been employed for the enhancement 
or attenuation of gene expression in a more reliable manner as 
compared to previous genome engineering techniques. The 
innovative use of the CRISPR system has been implemented to 
modulate gene expression through the alteration of epigenetic 
modifiers or crucial noncoding RNAs. Importantly, the 
CRISPR system is of utmost importance in delineating the 
role of non-coding RNAs (miRNAs, lncRNAs) which are often 
implicated in tumor progression and heterogeneity (Fig. 2). 
Finally, the CRISPR system constitutes a flexible platform that 
has been used for monitoring the localization of endogenous 
genes or cell fate in general.
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